Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

POLARx Post Approval Study (POLARx PAS)

NCT06170606 · View on ClinicalTrials.gov ↗

Study Summary

To collect clinical data on safety, effectiveness and procedural success of Boston Scientific's Cardiac Cryoablation System (includes all BSC commercially available POLARx/POLARx Fit catheters) when used to perform pulmonary vein isolation (PVI) in the ablation treatment of de novo Atrial Fibrillation (AF).

Interventions

  • DEVICE Boston Scientific Cardiac Cryoablation System

Study Locations (11)

Arizona

  • Mercy Gilbert Medical Center — Gilbert
  • Banner University Medical Center Phoenix — Phoenix
  • Pima Heart & Vascular Clinical Research — Tucson

Colorado

  • Intermountain Platte Valley Hospital — Brighton
  • Valley View Hospital — Glenwood Springs

California

  • Torrance Memorial Medical Center — Torrance

Florida

  • St. Joseph's Hospital/BayCare Medical Group — Tampa

Ohio

  • Bethesda North Hospital — Cincinnati

South Carolina

  • Prisma Health Richland Hospital — Columbia

Texas

  • University of Texas Medical Branch - Galveston — Galveston

Wisconsin

  • Aurora Health — Grafton

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-06-28
Est. Completion 2029-05
Phase NA

Sponsor

Boston Scientific Corporation

120 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06170606

The ClinicalTrials.gov registry entry for NCT06170606 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention — of which Boston Scientific Cardiac Cryoablation System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06170606 reports 11 study locations spanning 8 distinct geographic areas — top geographies include Arizona, Colorado, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06170606 about?

NCT06170606 is a clinical study titled "POLARx Post Approval Study (POLARx PAS)". To collect clinical data on safety, effectiveness and procedural success of Boston Scientific's Cardiac Cryoablation System (includes all BSC commercially available POLARx/POLARx Fit catheters) when used to perform pulmonary vein isolation (PVI) in the ablation treatment of de novo Atrial Fibrillati...

What is the current status of trial NCT06170606?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-06-28. Estimated completion is 2029-05.

What conditions does trial NCT06170606 study?

This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06170606?

The interventions under investigation include: Boston Scientific Cardiac Cryoablation System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06170606?

This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06170606 being conducted?

This trial has 11 study locations across Arizona, California, Colorado, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial